Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CTH | P32929 | 1/20 | 0.38 |
| ▸ | CBS | P35520 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672285 | 0.86 | HDAC1 (0.39) | FFAR3TSHRCTHCBSTHPO | |
| SCHEMBL25612553 | 0.84 | PAM (0.33) | FFAR3TSHRCTHCBSTHPO | |
| SCHEMBL8620614 | 0.83 | TSHR (0.35) | TSHRCTHCBSTHPOALDH1A1 | |
| SCHEMBL5374701 | 0.83 | CA2 (0.45) | TSHRPAM | |
| SCHEMBL15297865 | 0.83 | PAM (0.32) | TSHRCTHCBSTHPOALDH1A1 | |
| SCHEMBL28697890 | 0.81 | GRIK1 (0.32) | TSHRALDH1A1MMEACECPA1 | |
| SCHEMBL8689912 | 0.81 | GPR84 (0.44) | ACE2PAM | |
| SCHEMBL28697891 | 0.81 | GRIK1 (0.32) | TSHRALDH1A1MMEACECPA1 | |
| SCHEMBL3185207 | 0.81 | PAM (0.32) | TSHRALDH1A1MMEACECPA1 | |
| SCHEMBL28710900 | 0.81 | GRIK1 (0.32) | TSHRALDH1A1MMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | FFAR3 2160/4885TSHR 4527/4885CTH 288/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | FFAR3 103/4885TSHR 239/4885CTH 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.